Current labeling for approved checkpoint inhibitors in the indications evaluated by the FDA’s ODAC include broad approvals for all patients, regardless of PD-L1 expression.

Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co. The US regulator cleared BMS' LAG-3 drug relatlimab ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck ...

Checkpoint Therapeutics’ late entry into the PD-1/PD-L1 inhibitor category, cosibelimab, just got knocked back even further after it was turned down by the FDA as a treatment for skin cancer.

Trial in Recurrent Head and Neck Cancer ATLANTA, GA - June 24, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and ...

Checkpoint Therapeutics, Inc. announced that the U.S. FDA approved its drug UNLOXCYT™ (cosibelimab-ipdl) in December 2024, making it the first and only anti-PD-L1 treatment for adults with ...

Immune checkpoint inhibitors and their side effects. ... (2015). Opdivo (nivolumab): Second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma. https: ...

Discover a study that has raised concerns about the lack of dedicated mental health monitoring in genitourinary cancer therapy clinical trials.

CEL-SCI Corporation (NYSE American: CVM) today announced the potential positive impact on the clinical development of its immunotherapy Multikine® (Leukocyte Interleukin, Injection)* resulting ...